Amanda Cheung, Brent A. Neuschwander‐Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group – 29 April 2019 – Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed nations at risk of developing NASH cirrhosis and its complications.

Rahima A. Bhanji, Aldo J. Montano‐Loza, Kymberly D. Watt – 29 April 2019 – Sarcopenia is a common complication of cirrhosis and is defined as a progressive and generalized loss of skeletal muscle mass, strength, and function. Sarcopenia is associated with poor prognosis and increased mortality. How sarcopenia and muscle wasting relate to such poor outcomes requires looking beyond the overt muscle loss and at this entity as a systemic disease that affects muscles of vital organs including cardiac and respiratory muscles.

Patrick Starlinger, David Pereyra, Matthias Hackl, Alice Assinger – 29 April 2019

Abdulla Badawy – 29 April 2019

Jesus Prieto, Gloria Gonzalez‐Aseguinolaza – 26 April 2019

This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .

Yi‐Ming Li, Zhen‐Yu Liu, Jian‐Chao Wang, Jing‐Min Yu, Zhu‐Chun Li, Hai‐Jiao Yang, Juan Tang, Zhi‐Nan Chen – 25 April 2019 – Receptor‐interacting protein kinase 3 (RIP3) is the core regulator that switches cell death from apoptosis to necrosis. However, its role in tumor immunity is unknown. In this study, decreased RIP3 expression was observed in patients with hepatocellular carcinoma (HCC), which correlates with myeloid‐derived suppressor cell (MDSC) accumulation. Moreover, RIP3 is a prognosis factor for patients with HCC.

Alberto Ferrarese, Alessandro Vitale, Dino Sgarabotto, Francesco Paolo Russo, Giacomo Germani, Martina Gambato, Anna Maria Cattelan, Paolo Angeli, Umberto Cillo, Patrizia Burra, Marco Senzolo – 25 April 2019 – Bacterial infection (BI) is a major cause of worsening of liver function and death in patients with cirrhosis who are awaiting liver transplantation (LT). This study aimed to evaluate the outcome of LT candidates after a first episode of BI between January 2006 and December 2014 at Padua University Hospital.

Reina Sasaki, Subhayan Sur, Qi Cheng, Robert Steele, Ratna B. Ray – 25 April 2019 – Chronic hepatitis C virus (HCV) infection often leads to end‐stage liver disease, including hepatocellular carcinoma (HCC). We have previously observed reduced expression of microRNA‐30e (miR‐30e) in the liver tissues and sera of patients with HCV‐associated HCC, although biological functions remain unknown. In this study, we demonstrated that HCV infection of hepatocytes transcriptionally reduces miR‐30e expression by modulating CCAAT/enhancer binding protein β.

Vasantha L. Kolachala, Sirish K. Palle, Ming Shen, Asha Shenoi, Dmitry M. Shayakhmetov, Nitika A. Gupta – 25 April 2019 – Current understanding is that receptor interacting serine/threonine protein kinase 1 (RIPK1) can lead to two distinct forms of cell death: RIPK3‐mediated necroptosis or caspase 8 (Casp8)‐mediated apoptosis. Here, we report that RIPK1 signaling is indispensable for protection from hepatocellular injury in a steatotic liver undergoing ischemia reperfusion injury (IRI) but not in the lean liver.